These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 16708855)

  • 41. Natalizumab, multiple sclerosis, and primary central nervous system lymphoma: enigma, wrapped in mystery, enclosed in conundrum.
    Ransohoff RM
    Ann Neurol; 2009 Sep; 66(3):259-61. PubMed ID: 19798722
    [No Abstract]   [Full Text] [Related]  

  • 42. [Natalizumab in the treatment of multiple sclerosis].
    Horga A; Horga de la Parte JF
    Rev Neurol; 2007 Sep 1-15; 45(5):293-303. PubMed ID: 17876741
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Alpha4-integrin antagonism--an effective approach for the treatment of inflammatory diseases?
    Davenport RJ; Munday JR
    Drug Discov Today; 2007 Jul; 12(13-14):569-76. PubMed ID: 17631252
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Early relapses after the first dose of natalizumab in active multiple sclerosis patients.
    Centonze D; Furlan R; Gasperini C; Salvetti M; Battistini L
    Mult Scler; 2008 Sep; 14(8):1137-8. PubMed ID: 18701574
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The therapy of multiple sclerosis with immune-modulating or immunosuppressive drug. A critical evaluation based upon evidence based parameters and published systematic reviews.
    Clerico M; Rivoiro C; Contessa G; Viglietti D; Durelli L
    Clin Neurol Neurosurg; 2008 Nov; 110(9):878-85. PubMed ID: 18164542
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Still no evidence on the efficacy of immunomodulatory therapy in reducing functional impairment in multiple sclerosis].
    Vermeulen M
    Ned Tijdschr Geneeskd; 2007 Apr; 151(15):850-1. PubMed ID: 17472114
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Rituximab in a patient with multiple sclerosis--effect on B cells, plasma cells and intrathecal IgG synthesis.
    Petereit HF; Moeller-Hartmann W; Reske D; Rubbert A
    Acta Neurol Scand; 2008 Jun; 117(6):399-403. PubMed ID: 18031564
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Sustained-release fampridine for symptomatic treatment of multiple sclerosis.
    Korenke AR; Rivey MP; Allington DR
    Ann Pharmacother; 2008 Oct; 42(10):1458-65. PubMed ID: 18780812
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Natalizumab and central nervous system lymphoma: no clear association.
    Bozic C; LaGuette J; Panzara MA; Sandrock AW
    Ann Neurol; 2009 Sep; 66(3):261-2. PubMed ID: 19798645
    [No Abstract]   [Full Text] [Related]  

  • 50. [Therapy of multiple sclerosis].
    Simó M
    Neuropsychopharmacol Hung; 2009 Mar; 11(1):23-6. PubMed ID: 19731815
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Management of worsening multiple sclerosis with mitoxantrone: a review.
    Fox EJ
    Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Natalizumab treatment in pediatric multiple sclerosis: a case report.
    Borriello G; Prosperini L; Luchetti A; Pozzilli C
    Eur J Paediatr Neurol; 2009 Jan; 13(1):67-71. PubMed ID: 18406645
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Evolving therapies for multiple sclerosis.
    Korniychuk E; Dempster JM; O'Connor E; Alexander JS; Kelley RE; Kenner M; Menon U; Misra V; Hoque R; Gonzalez-Toledo E; Schwendimann RN; Smith S; Minagar A
    Int Rev Neurobiol; 2007; 79():571-88. PubMed ID: 17531859
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Natalizumab: a double-edged sword?
    DeAngelis LM
    Ann Neurol; 2009 Sep; 66(3):262-3. PubMed ID: 19798644
    [No Abstract]   [Full Text] [Related]  

  • 55. Natalizumab (Tysabri) returns.
    Med Lett Drugs Ther; 2006 Sep; 48(1243):76. PubMed ID: 16977289
    [No Abstract]   [Full Text] [Related]  

  • 56. At AAN, biotechs tout their wares for MS.
    Dalzell MD
    Manag Care; 2013 Jun; 22(6):55-6. PubMed ID: 23841137
    [No Abstract]   [Full Text] [Related]  

  • 57. Drug companies seek MS patients to lobby for new products.
    Yamey G
    BMJ; 2000 Jan; 320(7229):207. PubMed ID: 10642222
    [No Abstract]   [Full Text] [Related]  

  • 58. Disease activity free status: a new end point for a new era in multiple sclerosis clinical research?
    Bevan CJ; Cree BA
    JAMA Neurol; 2014 Mar; 71(3):269-70. PubMed ID: 24395449
    [No Abstract]   [Full Text] [Related]  

  • 59. The new era of multiple sclerosis therapeutics.
    Bakshi R
    Neurotherapeutics; 2013 Jan; 10(1):1. PubMed ID: 23238890
    [No Abstract]   [Full Text] [Related]  

  • 60. Evaluating epigenetic landmarks in the brain of multiple sclerosis patients: a contribution to the current debate on disease pathogenesis.
    Casaccia-Bonnefil P; Pandozy G; Mastronardi F
    Prog Neurobiol; 2008 Dec; 86(4):368-78. PubMed ID: 18930111
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.